Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Huperzine A vs Saffron: Saffron has the stronger overall evidence (7.5 vs 6/10); they're alternatives for sharpen focus — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Saffron wins 3 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
1 of 2 studies with measurable effects showed benefit.
Top outcomes
Verdict
Likely helps
5 of 5 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (2)
Outcomes where both Huperzine A and Saffron have evidence — compare verdict strength side-by-side.
50-200mcg twice daily
Morning and early afternoon, Avoid evening (may cause vivid dreams)
Huperzine A capsules (standardized extract)
28-30mg daily
Morning or split AM/PM
Affron® standardized extract
and 1 more not shown
2-4 weeks
30-60 minutes
2-4 weeks
During use
4-8 weeks
4-8 weeks
2 menstrual cycles
The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis
Psychopharmacology (2018) · Meta analysis · n=44854
The pooled standardized mean difference of the treatment effects on cognitive dysfunction was 0.439 (95% confidence interval 0.374, 0.504).
Traditional Chinese herbal medicine for vascular dementia
The Cochrane database of systematic reviews (2018) · Systematic review · n=3581
Two TCHMs (NaoMaiTai and TongXinLuo) had a 5% or more increased risk of AEs compared to the 'no Treatment' control, but the quality of this evidence was poor.
Interventions to delay functional decline in people with dementia: a systematic review of systematic reviews
BMJ open (2016) · Systematic review · n=70
The quality of the reviews varied; however most (65%) scored 8/11 or more on the AMSTAR tool, indicating high quality.
Comparative efficacy and tolerability of nutraceuticals for depressive disorder: A systematic review and network meta-analysis
Psychological medicine (2025) · Meta analysis · n=17437
Hundred and ninety-two trials involving 17,437 patients and 44 nutraceuticals were eligible for inclusion.
Systematic Review and Network Meta-Analysis of the Effects of Plant Extracts on Cognitive Function and Quality of Life in Stroke Patients
Phytotherapy research : PTR (2025) · Meta analysis · n=6599
48 eligible randomized controlled trials were included, covering 6599 stroke patients and evaluating nine different plant extract treatments, one of which was Crocus sativus (saffron).
New horizons for the study of saffron (Crocus sativus L.) and its active ingredients in the management of neurological and psychiatric disorders: A systematic review of clinical evidence and mechanisms
Phytotherapy research : PTR (2024) · Systematic review
A random-effects or fixed-effects model was used to calculate the pooled effect sizes.
Doses are per day. At 200 mcg (0.1 mg twice daily), a double-blind trial in 78 people with mild to moderate vascular dementia improved MMSE, CDR and daily living scores over 12 weeks (PMID 21833673). At 400 mcg (200 mcg twice daily), the primary analysis of a phase II trial in 210 people with Alzheimer's disease found no effect on ADAS-Cog at 16 weeks, so the curve stays flat rather than rising (PMID 21502597). At 800 mcg (400 mcg twice daily), the same trial found a 2.27-point ADAS-Cog gain at 11 weeks that was no longer significant at 16 weeks. A meta-analysis of four trials using 300 to 500 mcg a day found MMSE and daily living gains (PMID 19221692). The trials are in different populations and only one compared doses, so no minimum, optimal or safe ceiling is set.
Both points are doses of a standardised saffron extract (affron) in adults with low mood. A 4-week RCT in 128 adults (PMID 28735826) gave 22 or 28 mg a day: mood improved at 28 mg (POMS total mood disturbance versus placebo, d = -1.10) with no effect at 22 mg. A 12-week RCT in 202 adults with subclinical depressive symptoms (PMID 40414301) confirmed a smaller benefit at 28 mg (DASS-21 depression, d = 0.39). Doses above 28 mg were not compared with lower ones in these trials, so no optimal dose or safety ceiling is plotted. The cited depression meta-analyses pool trials without comparing doses.
AI-estimated from published studies. Interpret as directional guidance.
Saffron has a higher evidence score (7.5/10 vs 6/10) and wins in 3 of 3 categories.
For sharpen focus, Huperzine A has a higher relevance score (80 vs 48).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
Saffron, EPA omega-3, SAMe have real adjunct evidence — but these aren’t a substitute for care, and some interact dangerously.
Ashwagandha, L-theanine, magnesium, saffron — what actually helps stress, and the safety caveats.
The transition years (40s): cycle changes, mood, sleep, brain fog — foundations, vitex, and starting muscle work early.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.